SCHEMBL3050796

SCHEMBL3050796

COC1C(C)=C(C)C(OC)C(C)=C1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27754994 0.52
SCHEMBL2379897 0.51
SCHEMBL15427202 0.51
SCHEMBL10985274 0.48
SCHEMBL11570083 0.48
SCHEMBL10985271 0.48
SCHEMBL10985269 0.48
SCHEMBL11239093 0.47
SCHEMBL2207214 0.47
SCHEMBL1468768 0.43

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220055975-A1 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS PTC THERAPEUTICS, INC. 2022-02-24 US disclosed
US-11021424-B2 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers PTC THERAPEUTICS, INC. (US) 2021-06-01 US disclosed
EP-1933821-B1 TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS PTC THERAPEUTICS INC (US) 2020-07-29 EP disclosed
EP-2564843-B1 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers BIOELECTRON TECH CORP (US) 2018-12-26 EP disclosed
EP-2471530-B1 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS EDISON PHARMACEUTICALS INC (US) 2017-01-11 EP disclosed
US-9447006-B2 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers EDISON PHARMACEUTICALS, INC. (US) 2016-09-20 US disclosed
EP-1888059-B1 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS EDISON PHARMACEUTICALS INC (US) 2014-12-17 EP disclosed
EP-2564842-A1 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Edison Pharmaceuticals, Inc. (US) 2013-03-06 EP disclosed
EP-2564843-A1 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Edison Pharmaceuticals, Inc. (US) 2013-03-06 EP disclosed
EP-2471530-A1 Redox-active Therapeutics For Treatment Of Mitochondrial Diseases And Other Conditions And Modulation Of Energy Biomarkers Edison Pharmaceuticals, Inc. (US) 2012-07-04 EP disclosed
US-20100222436-A1 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS PTC THERAPEUTICS, INC. 2010-09-02 US disclosed
US-7432305-B2 Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers EDISON PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
EP-1933821-A1 TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS Edison Pharmaceuticals, Inc. (US) 2008-06-25 EP disclosed
EP-1888059-A2 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMAKERS Edison Pharmaceuticals, Inc. (US) 2008-02-20 EP disclosed
WO-2007035496-A1 TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS EDISON PHARMACEUTICALS, INC. (US) 2007-03-29 WO disclosed
US-20070072943-A1 Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers PTC THERAPEUTICS, INC. 2007-03-29 US disclosed
US-20060281809-A1 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers PTC THERAPEUTICS, INC. 2006-12-14 US disclosed
WO-2006130775-A2 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMAKERS EDISON PHARMACEUTICALS, INC. (US) 2006-12-07 WO disclosed